© Globe Newswire
03.09.2024
QGEN
LISTED
NYSE
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE....
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2024
NSIS B
LISTED
CPH
Trading by management and close relations of management
News Preview
Please read the full announcement in PDF...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.09.2024
NSIS B
LISTED
CPH
Trading by management and close relations of management
News Preview
Please read the full announcement in PDF...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© Globe Newswire
02.09.2024
OXB
LISTED
LSE
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
News Preview
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
02.09.2024
GN
LISTED
CPH
Trading in GN Store Nord shares by board members, executives and associated persons
News Preview
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN Store Nord and/or persons closely associated with them....
Themefolio
Profiler
Peergroup
© Newsfile
02.09.2024
COPN
LISTED
SIX
Cosmo Pharmaceuticals Highlights Study Published in "The Lancet" Demonstrating the Efficacy of GI Genius(TM) in Colonoscopy Procedures
News Preview
Dublin, Ireland--(Newsfile Corp. - September 2, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”), the developer and manufacturer of the GI Genius™ intelligent endoscopy system, is pleased to announce the publication of a landmark study in &#...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2024
FAGR
LISTED
EURONEXT
Fagron’s share buy-back program: Weekly update
News Preview
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 30 August 2024 – 6PM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2024
COLO B
LISTED
CPH
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
News Preview
Please see enclosed pdf....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2024
ZEAL
LISTED
CPH
Total number of shares and voting rights in Zealand Pharma on August 30, 2024
News Preview
Company announcement – No. 42 / 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2024
COLO B
LISTED
CPH
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
News Preview
Please see enclosed pdf....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2024
KDEV
LISTED
STO
Karolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005
News Preview
STOCKHOLM, Sweden, August 30 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has treated the first patient with the drug candidate BSG005 in the ongoing clinical trial in India. The treatment of the patient, who was diagnosed with mucormycosis (black fungus), proved to be very successful...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.08.2024
NSIS B
LISTED
CPH
Trading by management and close relations of management
News Preview
Please read the full announcement in PDF...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
30.08.2024
KDEV
LISTED
STO
Interim Report - January-June 2024
News Preview
STOCKHOLM – 30 August 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-June 2024. The full report is available on the Company's website....
Themefolio
Profiler
Peergroup
© PR Newswire
29.08.2024
SOBI
LISTED
STO
Sobi has completed issues of class C shares
News Preview
STOCKHOLM, Aug. 29, 2024 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 14 May 2024 resolved on directed issues of redeemable and convertible class C shares and to authorise the Board of Directors to resolve on the repurchase of all issued class C shares through an acquisition offer directed to all own...
Themefolio
Profiler
Peergroup
© PR Newswire
29.08.2024
SOBI
LISTED
STO
Sobi has completed issues of class C shares
News Preview
STOCKHOLM, Aug. 29, 2024 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 14 May 2024 resolved on directed issues of redeemable and convertible class C shares and to authorise the Board of Directors to resolve on the repurchase of all issued class C shares through an acquisition offer directed to all own...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2024
NSIS B
LISTED
CPH
Major shareholder announcement
News Preview
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments....
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2024
ANAB
LISTED
NASDAQ
Anaptys Announces Participation in September Investor Conferences
News Preview
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multi...
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2024
ORY
LISTED
BME
ORYZON to Provide Corporate Progress Updates at Several Events in September
News Preview
MADRID, Spain and CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give an update on corporate progress at several inte...
Themefolio
Profiler
Peergroup
© EQS Newswire
29.08.2024
1SXP
LISTED
XETR
SCHOTT Pharma erzielt starke Ergebnisse im dritten Quartal und erhöht Umsatzprognose für das Geschäftsjahr 2024
News Preview
SCHOTT Pharma erzielt starke Ergebnisse im dritten Quartal und erhöht Umsatzprognose für das Geschäftsjahr 2024
Q3 2024 Umsatzerlöse steigen währungsbereinigt um 21 % gegenüber Vorjahr auf 268 Mio. Euro
Starke Q3 2024 währungsbereinigte EBITDA-Marge von 28,2 %
Umsatzanteil der margenstarken High-Value-Lösungen (HVS) bei 53 % in den ersten neun ......
Themefolio
Profiler
Peergroup
© EQS Newswire
29.08.2024
1SXP
LISTED
XETR
SCHOTT Pharma delivers strong third quarter results and raises FY 2024 revenue guidance
News Preview
SCHOTT Pharma delivers strong third quarter results and raises FY 2024 revenue guidance
Q3 2024 revenues up 21% yoy to EUR 268m at constant currencies
Strong Q3 2024 EBITDA margin of 28.2% at constant currencies
Share of strong-margin high-value solutions (HVS) at 53% in the first nine month of FY 2024
SCHOTT Pharma increases revenue guidance ......
Themefolio
Profiler
Peergroup
© Globe Newswire
29.08.2024
IBAB
LISTED
EURONEXT
IBA Reports Half Year 2024 Results
News Preview
GROUP REVENUES UP 21.9%...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
SLP
LISTED
NASDAQ
Simulations Plus to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conferen...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
TEM
LISTED
NASDAQ
Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, held in New York, NY.
Tempus Founder and CEO, Eric Lefkofsky, will speak in a fireside discussion at the confer...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
BLUE
LISTED
NASDAQ
bluebird bio Announces September Investor Events
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferences:
2024 Wells Fargo Healthcare Conference, Wednesday, September 4, at 12:45 p.m. ET at the Encore Boston Harbor, Everett, MA
Morgan Stanley 22nd Annual Global Healthcare Confere...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2024
ASND
LISTED
NASDAQ
Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024
News Preview
COPENHAGEN, Denmark, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2024 financial results and provide a business update on Tuesday, September 3, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on September 3,...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.08.2024
AGFB
LISTED
EURONEXT
The Agfa-Gevaert Group in Q2 2024: solid quarter, powered by growth engines - regulated information - inside information
News Preview
Regulated information – Inside information August 28, 2024 - 7:45 a.m. CET The Agfa-Gevaert Group in Q2 2024: solid quarter, powered by growth engines...
Themefolio
Profiler
Peergroup
© BusinessWire
28.08.2024
HELP
LISTED
NASDAQ
Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation
News Preview
Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company’s annual and s...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2024
NSIS B
LISTED
CPH
Novonesis delivers strong half-year results and increases full-year outlook
News Preview
In the first half of 2024, Novonesis delivered 7% organic sales growth with an adjusted EBITDA margin at 35.3%. Following strong first half-year performance, Novonesis increases its full-year organic sales outlook from 5-7% to 7-8% and increases adjusted EBITDA-margin expectations from 35-36% to 35.5-36.5%....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2024
NSIS B
LISTED
CPH
Interim Report H1 2024
News Preview
H1 organic pro forma sales growth at 7%, with pro forma adjusted EBITDA margin at 35.3%. Full-year outlook increased. ...
Themefolio
Profiler
Peergroup
© BusinessWire
27.08.2024
ZLAB
LISTED
NASDAQ
Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from a Phase 1 study of ZL-1218, the company’s anti-CCR8 antibody, will be presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13-17, 2024, in Barcelona, Spain. The preliminary results from the ongoing dose-escala...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2024
NSIS B
LISTED
CPH
Novonesis increases outlook for full year 2024
News Preview
Novonesis increases its full-year sales and profitability outlook based on the first half year performance coupled with strong momentum going into the first months of the second half.The 2024 outlook is increased to:• Pro forma organic sales growth of now 7-8% (previously “upper end of 5-7%”)• Pro forma adjusted EBITDA margin of now 35.5-36.5% (pre...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2024
MURA
LISTED
NASDAQ
Mural Oncology to Present at Two Upcoming Investor Conferences
News Preview
WALTHAM, Mass. and DUBLIN, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that members of its management team will participat...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
BIOA B
LISTED
STO
Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology
News Preview
STOCKHOLM, Aug. 27, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the results from two phase-1 studies with exidavnemab have been published in The Journal of Clinical Pharmacology. Exidavnemab is a drug candidate under development aimed at treating diseases such as Parkinson's disease. It is a monoclonal...
Themefolio
Profiler
Peergroup
© PR Newswire
27.08.2024
BIOA B
LISTED
STO
Study results from phase 1 studies with exidavnemab published in The Journal of Clinical Pharmacology
News Preview
STOCKHOLM, Aug. 27, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the results from two phase-1 studies with exidavnemab have been published in The Journal of Clinical Pharmacology. Exidavnemab is a drug candidate under development aimed at treating diseases such as Parkinson's disease. It is a monoclonal...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2024
BAVA
LISTED
CPH
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore
News Preview
COPENHAGEN, Denmark, August 27, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced today that Singapore’s medicines regulatory authority, Health Sciences Authority (HSA), has approved JYNNEOS® (MVA-BN) for prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for smallpox or mpox infection....
Themefolio
Profiler
Peergroup
© Globe Newswire
27.08.2024
IBAB
LISTED
EURONEXT
IBA secures deal with the University of Pennsylvania Health System for two Proteus®ONE proton therapy solutions
News Preview
Agreement further strengthens the long-term relationship between IBA and the University of Pennsylvania...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2024
INDV
LISTED
NASDAQ
Indivior Announces BARDA's First Order of OPVEE® to Combat Opioids and Aid in National Preparedness
News Preview
BARDA purchased OPVEE, a nalmefene opioid overdose reversal nasal sprayThrough BARDA's contract with Indivior, communities will be better equipped to respond to mass poisoning emergencies and address biosecurity threats involving synthetic opioidsRICHMOND, Va., Aug. 26, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced the firs...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2024
GMAB
LISTED
CPH
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
Media ReleaseCOPENHAGEN, Denmark; August 26, 2024...
Themefolio
Profiler
Peergroup
© EQS Newswire
26.08.2024
PHARM
LISTED
EURONEXT
First Berlin Equity Research GmbH: Pharming Group NV | Rating: Buy
News Preview
Original-Research: Pharming Group NV - from First Berlin Equity Research GmbH
26.08.2024 / 15:55 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclu......
Themefolio
Profiler
Peergroup
© Globe Newswire
26.08.2024
SKYE
LISTED
NASDAQ
Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences
News Preview
SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that it will participate in the following upcoming healthcare investment conferences:...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.08.2024
SKYE
LISTED
NASDAQ
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on August 22, 2024, the Board of Directors granted a non-qualified stock option award to purchase 40,000 shares of its commo...
Themefolio
Profiler
Peergroup
© BusinessWire
23.08.2024
ERF
LISTED
EURONEXT
The Eurofins Network Announces Availability of Real-Time PCR Assay for the Identification of the Mpox Virus (Formerly Monkeypox), as WHO Declares Mpox a Public Health Emergency of International Concern and Health Authorities Recommend Increased...
News Preview
The Eurofins Network Announces Availability of Real-Time PCR Assay for the Identification of the Mpox Virus (Formerly Monkeypox), as WHO Declares Mpox a Public Health Emergency of International Concern and Health Authorities Recommend Increased Testing
Eurofins Scientific (EUFI.PA), a global leader in bioanalytical testing, announces the ava...
Themefolio
Profiler
Peergroup
© BusinessWire
23.08.2024
BLUE
LISTED
NASDAQ
bluebird bio Announces Receipt of Expected Notices from Nasdaq
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received notices (the “notices”) on August 20, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2024 (the “Q1 2024 Form 10-Q”) and June 30, 2024 (the “Q2 2024 Form...
Themefolio
Profiler
Peergroup
© PR Newswire
23.08.2024
HNSA
LISTED
STO
Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
News Preview
LUND, Sweden, Aug. 23, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (Nasdaq Stockholm: HNSA), today announced that Matthew Shaulis, Chief Commercial Officer and US President has decided to leave the company in late September. Effective immediately, the Commercial Leadership team will report to Søren Tulstrup, President and...
Themefolio
Profiler
Peergroup
© PR Newswire
23.08.2024
HNSA
LISTED
STO
Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
News Preview
LUND, Sweden, Aug. 23, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa" or the "Company") (Nasdaq Stockholm: HNSA), today announced that Matthew Shaulis, Chief Commercial Officer and US President has decided to leave the company in late September. Effective immediately, the Commercial Leadership team will report to Søren Tulstrup, President and...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.08.2024
FAGR
LISTED
EURONEXT
Fagron’s share buy-back program: Weekly update
News Preview
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 23 August 2024 – 6PM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.08.2024
BAVA
LISTED
CPH
Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
News Preview
COPENHAGEN, Denmark, August 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such....
Themefolio
Profiler
Peergroup
© BusinessWire
23.08.2024
SLP
LISTED
NASDAQ
Simulations Plus Optimizes Business Unit Structure to Support Future Growth Following Recent Strategic Acquisitions
News Preview
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced the optimization of its business unit and leadership structure to support future growth following the Company’s recent acqu...
Themefolio
Profiler
Peergroup
© Globe Newswire
23.08.2024
GLPG
LISTED
EURONEXT
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma
News Preview
Mechelen, Belgium; August 23, 2024, 07:00 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the U.S. Food and Drug Administration (FDA) has cleared Galapagos’ Investigational New Drug (IND) application for ATALANTA-1, a Phase 1/2 multicenter study evaluating the feasibility, safety, an...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
GETI B
LISTED
STO
Getinge to acquire Paragonix Technologies, a growth leader in the organ transplantation market
News Preview
Today, Getinge announces an agreement to acquire 100% of Paragonix Technologies, Inc., a leading organ transport products and services company in the United States for an aggregated purchase price, including upfront and earn out payments, estimated to approximately USD 477 million.
GOTHENBURG, Sweden, Aug. 23, 2024 /PRNewswire/ -- With the acquis...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
GETI B
LISTED
STO
Getinge to acquire Paragonix Technologies, a growth leader in the organ transplantation market
News Preview
Today, Getinge announces an agreement to acquire 100% of Paragonix Technologies, Inc., a leading organ transport products and services company in the United States for an aggregated purchase price, including upfront and earn out payments, estimated to approximately USD 477 million.
GOTHENBURG, Sweden, Aug. 22, 2024 /PRNewswire/ -- With the acquis...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
CU6
LISTED
ASX
Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA
News Preview
SYDNEY, Aug. 22, 2024 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track De...
Themefolio
Profiler
Peergroup
© BusinessWire
22.08.2024
ZLAB
LISTED
NASDAQ
Zai Lab Announces Participation in September Investor Conferences
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in September 2024:
Morgan Stanley 22nd Annual Global Healthcare Conference
Location: New York, New York
Cantor Fitzgerald Global Healthcare Conference
Fireside Chat: Thursday,...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
BIOA B
LISTED
STO
Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain
News Preview
STOCKHOLM, Aug. 22, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain, for the treatment of mild cognitive impairment (MCI)...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
BIOA B
LISTED
STO
Leqembi (lecanemab) authorized for early Alzheimer's disease in Great Britain
News Preview
STOCKHOLM, Aug. 22, 2024 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing Authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) in Great Britain, for the treatment of mild cognitive impairment (MCI)...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.08.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
News Preview
CBeyond™ will assess nimacimab’s ability to safely induce weight loss, and will also evaluate a combination of a GLP-1 receptor agonist plus nimacimab CBeyond™ will assess nimacimab’s ability to safely induce weight loss, and will also evaluate a combination of a GLP-1 receptor agonist plus nimacimab...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.08.2024
VLA
LISTED
EURONEXT
First Berlin Equity Research GmbH: Valneva | Rating: Buy
News Preview
Original-Research: Valneva - von First Berlin Equity Research GmbH
22.08.2024 / 10:50 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Au......
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
BIOA B
LISTED
STO
Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
News Preview
STOCKHOLM, Aug. 22, 2024 /PRNewswire/ -- British media are reporting on the imminent approval of lecanemab in Great Britain. BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) has currently not been informed that the relevant authorities have made a decision and cannot therefore comment on these rumors. The company will update the market if new infor...
Themefolio
Profiler
Peergroup
© PR Newswire
22.08.2024
BIOA B
LISTED
STO
Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
News Preview
STOCKHOLM, Aug. 22, 2024 /PRNewswire/ -- British media are reporting on the imminent approval of lecanemab in Great Britain. BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) has currently not been informed that the relevant authorities have made a decision and cannot therefore comment on these rumors. The company will update the market if new infor...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.08.2024
ORNBV
LISTED
HEL
Orion Corporation: Managers’ transactions – Satu Ahomäki
News Preview
ORION CORPORATION MANAGERS’ TRANSACTIONS 22 AUGUST 2024 at 10.30 EEST ...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
